Changes in Hong Kong stocks | Gacos-B (01167) rose more than 6% in the intraday period. Affiliates received 125 million payments from the head of state, and the combination therapy appeared in “The Lancet”

The Zhitong Finance App learned that Gacos-B (01167) rose more than 6% in the intraday period. As of press release, it had risen 5.51% to HK$8.04, with a turnover of HK$8.152,500.

According to the news, Gacos announced that Beijing Gacos, a subsidiary of the company, has received an initial payment of RMB 125 million from Haisong Capital. The receipt of this down payment has further filled the Group's cash reserves and will also help advance the Group's subsequent research and development of innovative oncology therapy pipelines.

Furthermore, Gacos recently announced that the clinical phase I/IIa research results of the KRAS G12C inhibitor glecirasib (glecirasib) and the SHP2 inhibitor JAB-3312 (sitneprotafib) developed by the company were officially published in the top international medical journal “Lancet Respiratory Medicine” (impact factor 32.8). This is the first time in the world that systematic clinical data on KRAS G12C and SHP2 dual-oral small molecule combination therapy has appeared in this authoritative journal.